Guanxin Pharmaceutical Technology Co., Ltd.
Guanxin Pharmaceutical Technology Co., Ltd., a prominent player in the pharmaceutical industry, is headquartered in China (CN) and operates extensively across various regions. Founded in [year], the company has established itself as a leader in the development and manufacturing of innovative pharmaceutical products and technologies. Specialising in [specific areas, e.g., active pharmaceutical ingredients (APIs), formulations, or biotechnology], Guanxin Pharmaceutical is recognised for its commitment to quality and cutting-edge research. The company’s core offerings include [list core products/services], which are distinguished by their efficacy and safety profiles. With a strong market position, Guanxin Pharmaceutical has achieved notable milestones, including [mention any key achievements or recognitions]. As it continues to expand its global footprint, the company remains dedicated to advancing healthcare solutions and improving patient outcomes.
DitchCarbon Score
How does Guanxin Pharmaceutical Technology Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Guanxin Pharmaceutical Technology Co., Ltd.'s score of 13 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Guanxin Pharmaceutical Technology Co., Ltd.'s reported carbon emissions
In 2023, Guanxin Pharmaceutical Technology Co., Ltd. reported total carbon emissions of approximately 1,133,129 kg CO2e, comprising 296,952 kg CO2e from Scope 1, 813,827 kg CO2e from Scope 2, and 42,350 kg CO2e from Scope 3 emissions, which included 8,632 kg CO2e from waste generated in operations. The company's emissions data from previous years shows a slight decrease in Scope 1 emissions from 323,979 kg CO2e in 2021 to 296,952 kg CO2e in 2023, while Scope 2 emissions decreased from 924,387 kg CO2e in 2021 to 813,827 kg CO2e in 2023. Scope 3 emissions were first reported in 2023, indicating a growing awareness of the full impact of their operations. Despite these figures, Guanxin Pharmaceutical has not set specific reduction targets or climate pledges, which may limit their ability to demonstrate a commitment to long-term sustainability. The absence of documented reduction initiatives suggests that the company is still in the early stages of developing a comprehensive climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | 000,000 | 000,000 | 000,000 |
| Scope 2 | 901,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Guanxin Pharmaceutical Technology Co., Ltd. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
